Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt

Next Previous
Search
Trial Profile

A Randomised, Phase II Study to Evaluate the sAfety and Pharmacokinetics of oraL dabIGatran Etexilate in Patients After Heart Valve replacemeNt

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 12 Jan 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Stroke; Thromboembolism; Thrombosis
  • Focus Adverse reactions; Pharmacokinetics
  • Acronyms RE-ALIGN
  • Sponsors Boehringer Ingelheim Pharmaceuticals

Most Recent Events

  • 11 Jan 2022 This trial has been completed in Norway (End Date: 03 Jun 2013), according to European Clinical Trials Database record.
  • 01 Sep 2013 Data were presented at the 2013 European Society of Cardiology (ESC) congress and published in the New England Journal of Medicine, according to a Boehringer Ingelheim media release.
  • 26 Aug 2013 Results will be presented at the 2013 European Society of Cardiology Congress (ESC-2013) according to a Boehringer Ingelheim media release.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top